ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0712

Targeting Nox with Pan-Nox Inhibitor in Aging Diabetic Kidney

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Yoon, Sung Gi, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Cha, Jin Joo, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Park, Booyeun, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Ghee, Jungyeon, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Yoo, Ji ae, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Kang, Young Sun, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
  • Cha, Dae R., Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea (the Republic of)
Background

Aging process is a risk factor for altered glucose metabolism and insulin resistance. Moreover, diabetes with serious complications has been steadily increasing in older patients. Chronic inflammation and increased oxidative stress are commonly shared features of aging and diabetes mellitus. Therefore, we investigated the effect of pan-nox inhibitor on aging diabetic mice.

Methods

Diabetes was induced by intraperitoneal injection of streptozotocin at a 50mg/kg/day for 5 days in 52-week-old week C57BL/6J mice. An orally active pan-nox inhibitor from Aptabio was administered by oral gavage at a dose of 60mg/kg/day for 12 weeks in aging mice and diabetes induced aging mice.

Results

Nox inhibition significantly improved insulin resistance in both aging and diabetic aging mice. Additionally, fasting glucose and HbA1c level were significantly improved with Nox inhibition in diabetic aging group. Interestingly, oxidative stress measured by 8-isoprostane was significantly increased in both aging and diabetic mice. Pan-nox inhibitor significantly reduced plasma 8-isoprostane level in aging group, and urinary 8-isoprostane level in diabetic group. In diabetic aging condition, there was trend to decrease in urinary albumin and nephrin excretion with nox inhibition. .Simply aging did not significantly altered PAI-1 and collagen IV expressions in the kidney compared to diabetic condition. However, nox 1 and 4 expressions was as well as increased in aging mice and diabetic mice. Pan-nox inhibitor significantly reduced renal PAI-1, collagen IV expressions in diabetic aging mice. Klotho level was significantly reduced in both aging and diabetic mice and nox inhibition restored klotho level in aging mice, but not in diabetic mice.

Conclusion

Our results provide evidence that pan-nox inhibition may improve systemic insulin resistance and oxidative stress in aging diabetic status, and therefore may have potential protective effects on aging diabetic kidney.